Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. (NYSE: A) is a global company in analytical and clinical laboratory technologies, and its news flow reflects activity across life sciences, diagnostics, and applied markets. Company announcements highlight how Agilent’s instruments, software, services, and expertise are used to help customers bring great science to life, as well as how it manages its financial performance and corporate governance.
On this page, readers can follow Agilent news related to earnings results, product introductions, regulatory-focused solutions, capital allocation, and investor events. Recent releases include quarterly and full-year financial results, with details on revenue, net income, and segment performance for the Life Sciences and Diagnostics Markets Group, the Agilent CrossLab Group, and the Applied Markets Group. These updates often include management commentary on business conditions and outlook.
Agilent’s news also covers product and technology developments. For example, the company has announced 21 CFR Part 11 compliance software for the xCELLigence RTCA eSight system, designed to support use in GMP-regulated manufacturing and quality control environments by adding secure user authentication, electronic signatures, and audit trails. Another announcement introduced Agilent Altura Ultra Inert HPLC Columns, described as high performance liquid chromatography columns suited for biotherapeutics applications such as peptide GLP-1 and oligonucleotide therapeutic development and quality control.
Investors and analysts can also find updates on capital markets activities, such as cash dividend declarations on Agilent’s common stock, and notices of participation in healthcare and investor conferences. Governance-related news, including leadership transitions and executive appointments, is communicated through press releases and related SEC filings. Bookmarking this page allows users to review Agilent’s ongoing communications about its operations, technologies, financial performance, and corporate developments in one place.
Agilent Technologies (NYSE: A) announced its participation in Analytica 2022, taking place from June 21 to 24 in Munich, Germany. The company aims to showcase its latest innovations in mass spectrometry, including AI-driven instruments, which enhance lab productivity. Key products featured include the 6475 Triple Quadrupole LC/MS and 5977C GC/MSD, among others. Agilent emphasizes its commitment to sustainability through products labeled with My Green Lab ACT. Technical experts will be available for consultations at their booths, alongside hosting forum talks throughout the event.
Summary not available.
Agilent Technologies (NYSE: A) has announced the integration of its Alissa data analysis platform with NVIDIA's Clara Parabricks and Amazon EC2 G5g instances. This collaboration aims to enhance genomic data processing speeds, improving workflows for clinical labs and researchers. The integration supports Agilent's SureSelect NGS assays, allowing for cost-effective, targeted sequencing. The partnership with AWS focuses on leveraging global data security and cloud capabilities, enhancing efficiency and reducing analysis turnaround times for genomic experiments.
Agilent Technologies (NYSE: A) introduced new LC/MS and GC/MS mass spectrometers at the 70th ASMS Conference in Minneapolis, showcasing advancements in instrument intelligence that enhance lab operations. The Agilent 6475 triple quadrupole LC/MS offers improved analysis speed, while the 5977C GC/MSD introduces HydroInert technology for hydrogen use as a carrier gas. Agilent aims to facilitate sustainable lab choices through its partnership with My Green Lab. The company generated $6.32 billion in revenue in fiscal 2021, highlighting its strong market position in life sciences and diagnostics.
Agilent Technologies Inc. (NYSE: A) launched MassHunter BioConfirm 12.0 software, enhancing analysis for oligonucleotides in drug development. This update supports high-resolution LC/MS data, significantly improving oligonucleotide purity and sequence confirmation assessments. The software's new features allow researchers to confirm sequences in minutes instead of days, demonstrating Agilent's commitment to biopharma solutions. The software will be showcased at the 70th ASMS Conference in Minneapolis, from June 5-9, 2022.
Agilent Technologies Inc. (NYSE: A) will participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15 in Rancho Palos Verdes, California. CEO Mike McMullen and CFO Bob McMahon will engage in a fireside chat starting at 10 a.m. PT (1 p.m. ET). Interested parties can access the live event via Agilent’s investor relations website, with a replay available within 24 hours. Agilent is a leader in life sciences and diagnostics, generating $6.32 billion in revenue in fiscal 2021.
Agilent Technologies Inc. (NYSE: A) announced the release of its IVDR Class A instruments, kits, and reagents on May 26, 2022, aligning with the EU's In Vitro Diagnostic Regulation (IVDR). This transition allows labs in the EU to use Agilent products without interruption, enhancing patient safety and regulatory compliance. Agilent's Class A products encompass a wide range of solutions, addressing challenges posed by the COVID pandemic. The company reported $6.32 billion in revenue for fiscal 2021 and boasts a global workforce of 17,000.
RTX A/S has announced the expansion of its audio module series supporting the Sheerlink product solutions during the NAMM show held in
Agilent Technologies Inc. (NYSE: A) has entered a collaboration with APC Ltd. to enhance automated process analysis using liquid chromatography. This partnership aims to deliver innovative workflows that merge analytical and process solutions, supporting the pharmaceutical and biopharmaceutical industries in accelerating drug development. Both companies emphasize the importance of continuous manufacturing and online process monitoring, which will be showcased through webinars and application notes featuring Agilent's InfinityLab Online LC and InfinityLab Bio LC portfolio. Agilent generated $6.32 billion in revenue in fiscal 2021.
Agilent Technologies reported a strong second quarter with revenue of $1.61 billion, reflecting a 5% increase year-over-year and 7% growth on a core basis. GAAP net income rose to $274 million or 91 cents per share, marking a 30% increase from Q2 2021. Non-GAAP earnings reached $340 million with an EPS of $1.13, up 16% year-over-year. The company raised its full-year revenue guidance to between $6.67 billion and $6.73 billion, projecting core growth of 8% to 9% and non-GAAP EPS of $4.86 to $4.93.
FAQ
What is the current stock price of Agilent Technologies (A)?
What is the market cap of Agilent Technologies (A)?
